RA
VKTX icon

Royce & Associates’s Viking Therapeutics VKTX Stock Holding History

Royce & Associates’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-75,261
Closed -$3.03M – 867
2024
Q4 		$3.03M Buy
75,261
+61,927
+464% +$3.53M 0.03% 565
2024
Q3 		$844K Buy
+13,334
New +$782K 0.01% 746
2024
Q2 		– Sell
-6,951
Closed -$570K – 916
2024
Q1 		$570K Sell
6,951
-21,086
-75% -$938K 0.01% 780
2023
Q4 		$522K Buy
+28,037
New +$367K ﹤0.01% 790
2019
Q1 		– Sell
-135,000
Closed -$1.03M – 1190
2018
Q4 		$1.03M Buy
+135,000
New +$1.61M 0.01% 853

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Royce & Associates's VKTX Position: Q1 2025 in Review

Royce & Associates sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 75,261 shares — an estimated $3.03M sold.

Royce & Associates first reported a position in VKTX in Q4 2018 and held it in 5 quarters. The position peaked at $3.03M in Q4 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Royce & Associates reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Royce & Associates sold 75,261 Viking Therapeutics shares in Q1 2025, an estimated $3.03M.
  • Royce & Associates first reported a position in Viking Therapeutics in Q4 2018 and held it in 5 quarters.
  • Royce & Associates's Viking Therapeutics position peaked at $3.03M in Q4 2024.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Royce & Associates's 13F filing for Q1 2025, filed 6 May 2025.